Author:
Nag Kakon,Mohiuddin Mohammad,Mahtab Mamun Al,Bachar Sitesh Chandra,Rahim Abdur,Uddin Helal,Kumar Samir,Khan Maksudur Rahman,Sarker Enamul Haq,Chowdhury Mashfiqur Rahman,Roy Rony,Chakraborty Sourav,Biswas Bipul Kumar,Bappi Emrul Hasan,Roy Ratan,Barman Uttam,Sultana Naznin
Abstract
AbstractBackgroundThe biosimilarity for erythropoietin (EPO) functionality of GBPD002 (test candidate) and Eprex®(comparator) has been evaluated by comparing the pharmacokinetic (PK) and pharmacodynamic (PD) properties following subcutaneous injection.MethodsThis was a randomized, double-blinded, two-sequence, crossover clinical trial. Subjects were randomly assigned and received a dose (4,000 IU) of either the test or comparator EPO, and received the alternative formulations after 4-weeks of washout period.ResultsThe PK parameters,viz., maximum observed concentration (Cmax) and area under the curve extrapolated to infinity (AUC0-inf), were calculated with the serum EPO concentrations from blood samples and were found comparable for both formulations. The geometric mean ratios (at 90% CI) of the Cmaxand AUCinfwere 0.89 and 1.16, respectively, which were within the regulatory range of 0.80 – 1.25. The time-matched serum EPO concentrations and PD markers (reticulocyte, hematocrit, hemoglobin, and red blood cell) denoted a counterclockwise hysteresis, suggesting a time delay between the observed concentration and the response. ANOVA-derivedP-values (>0.05) for the effectors clearly revealed the similarity between effects on PD markers for the test and comparator drugs. Both formulations were found tolerated well, and anti-drug antibodies were not observed.ConclusionsThus, the two formulations are projected to be used interchangeably in clinical settings.
Publisher
Cold Spring Harbor Laboratory
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献